FR2435905A1
(fr)
*
|
1978-09-13 |
1980-04-11 |
Anvar |
Nouveaux agents molluscicides derives du benzamido-2 nitro-5 thiazole
|
US4315018A
(en)
*
|
1978-12-07 |
1982-02-09 |
Rossignol Jean F |
Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
|
HU180396B
(en)
*
|
1979-12-21 |
1983-02-28 |
Wellcome Found |
Process for producing nitro-thiazoline derivatives
|
RU2140915C1
(ru)
*
|
1994-04-13 |
1999-11-10 |
Россиньоль Жан-Франсуа |
Производные бензамида, фармацевтическая композиция, галеновый препарат для перорального введения, мазь для лечения заболеваний нижнего отдела брюшной полости, смесь соединений, пищевая композиция
|
US5387598A
(en)
*
|
1994-04-13 |
1995-02-07 |
Rossignol; Jean-Francois |
Composition and galenic formulation suitable for combatting affections of the lower abdomen
|
US5578621A
(en)
*
|
1994-09-08 |
1996-11-26 |
Romark Lab Lc |
Benzamide derivatives
|
MX9604483A
(es)
*
|
1994-09-08 |
1998-02-28 |
Jean-Francois Rossignol |
Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
|
US5859038A
(en)
*
|
1994-09-08 |
1999-01-12 |
Romark Laboratories, L.C. |
Method for treatment of helicobacter pylori infections
|
US5968961A
(en)
*
|
1997-05-07 |
1999-10-19 |
Romark Laboratories, L.C. |
Pharmaceutical compositions of tizoxanide and nitazoxanide
|
AU756451B2
(en)
*
|
1997-05-07 |
2003-01-16 |
Romark Laboratories, L.C. |
Pharmaceutical compositions of tizoxanide and nitazoxanide
|
PL193275B1
(pl)
*
|
1997-05-07 |
2007-01-31 |
Romark Lab |
Środek farmaceutyczny oraz zastosowanie deacetylo-nitazoksanidu i/lub nitazoksanidu
|
US5935591A
(en)
*
|
1998-01-15 |
1999-08-10 |
Romark Laboratories, L.C. |
Method for treatment of equine protozoal myeloencephalitis with thiazolides
|
US5925622A
(en)
*
|
1998-07-13 |
1999-07-20 |
Romark Laboratories, L.C. |
Synthesis of aryl glucuronide of 2-hydroxy-N- (5-nitro-2-thiazolyl) benzamide, and pharmaceutical compositions comprising same
|
SE0102764D0
(sv)
*
|
2001-08-17 |
2001-08-17 |
Astrazeneca Ab |
Compounds
|
US7125568B2
(en)
*
|
2001-08-23 |
2006-10-24 |
Sung Michael T |
Lipophilic drug compositions
|
GB0226930D0
(en)
|
2002-11-19 |
2002-12-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0325402D0
(en)
*
|
2003-10-31 |
2003-12-03 |
Astrazeneca Ab |
Compounds
|
GB0327761D0
(en)
*
|
2003-11-29 |
2003-12-31 |
Astrazeneca Ab |
Compounds
|
GB0328178D0
(en)
*
|
2003-12-05 |
2004-01-07 |
Astrazeneca Ab |
Compounds
|
WO2005080359A1
(fr)
*
|
2004-02-18 |
2005-09-01 |
Astrazeneca Ab |
Dérivés de benzamide et leur utilisation en tant qu'activateurs de la glucokinase
|
BRPI0507734A
(pt)
*
|
2004-02-18 |
2007-07-10 |
Astrazeneca Ab |
composto ou um sal, pró-droga ou solvato do mesmo, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
|
TW200600086A
(en)
*
|
2004-06-05 |
2006-01-01 |
Astrazeneca Ab |
Chemical compound
|
UA90864C2
(en)
*
|
2004-09-09 |
2010-06-10 |
Ромарк Лебораториз, Л.К. |
Halogenated benzamide derivatives
|
US20060194853A1
(en)
*
|
2004-10-08 |
2006-08-31 |
Rossignol Jean F |
Alkyl benzamides
|
WO2006040527A1
(fr)
|
2004-10-16 |
2006-04-20 |
Astrazeneca Ab |
Procede de fabrication de composes de phenoxy benzamide
|
GB0423044D0
(en)
*
|
2004-10-16 |
2004-11-17 |
Astrazeneca Ab |
Compounds
|
GB0423043D0
(en)
*
|
2004-10-16 |
2004-11-17 |
Astrazeneca Ab |
Compounds
|
AU2006235490A1
(en)
*
|
2005-04-12 |
2006-10-19 |
Romark Laboratories, L.C. |
Methods for treating diseases through the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
|
US20110059941A1
(en)
*
|
2005-05-24 |
2011-03-10 |
Peter William Rodney Caulkett |
2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators
|
TW200714597A
(en)
*
|
2005-05-27 |
2007-04-16 |
Astrazeneca Ab |
Chemical compounds
|
NZ575514A
(en)
*
|
2005-07-09 |
2009-11-27 |
Astrazeneca Ab |
Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
|
US20080234273A1
(en)
*
|
2005-07-09 |
2008-09-25 |
Mckerrecher Darren |
Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes
|
EP1910350A1
(fr)
*
|
2005-07-09 |
2008-04-16 |
AstraZeneca AB |
Composés 2-hétérocyclyloxybenzoyl amino hétérocyclyle en tant que modulateurs de glucokinase pour le traitement du diabète de type 2
|
US9202182B2
(en)
*
|
2005-08-11 |
2015-12-01 |
International Business Machines Corporation |
Method and system for analyzing business architecture
|
TW200738621A
(en)
*
|
2005-11-28 |
2007-10-16 |
Astrazeneca Ab |
Chemical process
|
BRPI0706379A2
(pt)
|
2006-01-09 |
2011-03-22 |
Romark Lab Lc |
tratamento de hepatite viral
|
US7678791B2
(en)
*
|
2006-07-12 |
2010-03-16 |
Cumbre Ip Ventures, L.P. |
Nitroheteroaryl-containing rifamycin derivatives
|
CN100465169C
(zh)
*
|
2006-08-02 |
2009-03-04 |
杭州欣阳三友精细化工有限公司 |
硝唑尼特的制备方法
|
TW200825063A
(en)
*
|
2006-10-23 |
2008-06-16 |
Astrazeneca Ab |
Chemical compounds
|
CL2007003061A1
(es)
*
|
2006-10-26 |
2008-08-01 |
Astrazeneca Ab |
Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
|
TW200833339A
(en)
*
|
2006-12-21 |
2008-08-16 |
Astrazeneca Ab |
Novel crystalline compound
|
CN101007792B
(zh)
*
|
2007-01-31 |
2010-05-26 |
浙江大学 |
一种合成硝基噻唑苯酰胺化合物的方法
|
CN101835765B
(zh)
*
|
2007-08-03 |
2013-05-29 |
罗马克实验室有限公司 |
烷基磺酰基取代的噻唑化物类化合物
|
WO2010015849A2
(fr)
*
|
2008-08-04 |
2010-02-11 |
Astrazeneca Ab |
Agents thérapeutiques 414
|
TW201639852A
(zh)
|
2008-12-09 |
2016-11-16 |
吉李德科學股份有限公司 |
用於製備可用作類鐸受體調節劑之化合物的中間體化合物
|
AU2010213678B2
(en)
|
2009-02-13 |
2015-11-26 |
Romark Laboratories L.C. |
Controlled release pharmaceutical formulations of nitazoxanide
|
GB0902434D0
(en)
*
|
2009-02-13 |
2009-04-01 |
Astrazeneca Ab |
Chemical process
|
GB0902406D0
(en)
*
|
2009-02-13 |
2009-04-01 |
Astrazeneca Ab |
Crystalline polymorphic form
|
AR076220A1
(es)
|
2009-04-09 |
2011-05-26 |
Astrazeneca Ab |
Derivados de pirazol [4,5 - e] pirimidina
|
AR076221A1
(es)
*
|
2009-04-09 |
2011-05-26 |
Astrazeneca Ab |
Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
|
NZ596538A
(en)
*
|
2009-05-12 |
2014-04-30 |
Romark Lab Lc |
Haloalkyl heteroaryl benzamide compounds
|
CN108042535A
(zh)
*
|
2009-06-26 |
2018-05-18 |
罗马克实验室有限公司 |
用于治疗流感的化合物和方法
|
CN101602744B
(zh)
*
|
2009-06-30 |
2011-06-01 |
青岛康地恩药业有限公司 |
一种硝唑尼特的制备方法
|
US9498441B2
(en)
|
2012-01-27 |
2016-11-22 |
Siegfried Rhein S.A. De C.V. |
Nitazoxadine composition and process to prepare same
|
WO2014049397A1
(fr)
|
2012-09-27 |
2014-04-03 |
Siegfried Rhein S.A. De C.V. |
Composition synergique de nitazoxanide et de mébendazole, procédés de préparation correspondants et utilisation de cette composition dans le traitement de la parasitose humaine
|
US20160244435A1
(en)
*
|
2013-06-21 |
2016-08-25 |
The Scripps Research Institute |
Expanded therapeutic potential in nitroheteroaryl antimicrobials
|
MX2017000026A
(es)
|
2014-07-11 |
2017-05-01 |
Gilead Sciences Inc |
Moduladores de receptores tipo toll para el tratamiento de virus de inmunodeficiencia humana (vih).
|
SI3194401T1
(sl)
|
2014-09-16 |
2020-12-31 |
Gilead Sciences, Inc. |
Trdne oblike modulatorja toličnega receptorja
|
CN107105660A
(zh)
|
2014-11-11 |
2017-08-29 |
罗马克实验室有限公司 |
使用替唑尼特、其类似物或盐的前药的治疗组合物和治疗方法
|
CN105175352A
(zh)
*
|
2015-10-27 |
2015-12-23 |
杭州澳医保灵药业有限公司 |
一种硝唑尼特的制备方法
|
CN106831640A
(zh)
*
|
2015-12-03 |
2017-06-13 |
江苏正大丰海制药有限公司 |
一种硝唑尼特晶体的制备方法
|
DK3436074T3
(da)
|
2016-03-31 |
2020-08-03 |
Romark Laboratories Lc |
Thiazolidforbindelser til behandling af virale infektioner
|
EP3442580B1
(fr)
|
2016-04-11 |
2020-09-23 |
Genfit |
Procédés de traitement de la fibrose
|
SG11201906041QA
(en)
|
2017-01-27 |
2019-08-27 |
Genfit |
Pharmaceutical compositions for combination therapy
|
US11173149B2
(en)
|
2017-04-18 |
2021-11-16 |
Romark Laboratories L.C. |
Inhibition of protein disulfide-isomerase A3
|
JP2022528727A
(ja)
|
2019-04-12 |
2022-06-15 |
ジェンフィット |
酸化ストレスに関連する疾患の治療に使用するためのニタゾキサニド及びチアゾリド
|
CA3153784A1
(fr)
|
2019-10-28 |
2021-05-06 |
Nicolas STANKOVIC-VALENTIN |
Polytherapie d'elafibranor et de nitazoxanide comportant des caracteristiques antioxydantes
|
WO2022020243A1
(fr)
|
2020-07-20 |
2022-01-27 |
Romark Laboratories L.C. |
Sels cristallins de tizoxanide et de 2-hydroxy-n-(5-chloro-1,3-thiazol-2-yl)benzamide (rm-4848) avec de l'éthanolamine, de la morpholine, de la propanolamine, de la pipérazine et de la n-méthylpipérazine
|
JP2023538136A
(ja)
|
2020-08-24 |
2023-09-06 |
ロマーク ラボラトリーズ,リミティド カンパニー |
コロナウイルスに対するチアゾリドの利用
|
CN114044761B
(zh)
*
|
2021-02-24 |
2022-05-17 |
成都贝诺科成生物科技有限公司 |
一种新的硝基噻唑衍生物及其应用
|
WO2022218239A1
(fr)
*
|
2021-04-12 |
2022-10-20 |
杜心赟 |
Nouveau composé de thiazole, son procédé de préparation et son utilisation
|
CA3233848A1
(fr)
|
2021-10-05 |
2023-04-13 |
Sasidhar Balappa SOMAPPA |
Procede ameliore pour preparer du nitazoxanide et de ses intermediaires
|
CN116898846A
(zh)
*
|
2022-04-12 |
2023-10-20 |
成都贝诺科成生物科技有限公司 |
一种硝基噻唑衍生物在制备抑制幽门螺杆菌的抑菌剂中的用途
|